Tag Archives: shortages

Apple, AMD, and Intel shift priorities as chip shortages continue

Enlarge / Sure, it’s cheaply produced clip art… but it’s also a disturbingly accurate picture of the current state of supply and demand in the semiconductor product market.

2021’s infamous chip shortages aren’t only affecting automakers. In a post-earnings conference call Tuesday, Apple CEO Tim Cook said, “We’ll do everything we can to mitigate whatever circumstances we’re dealt”—a statement that likely means the company will ration its chip supplies, prioritizing the most profitable and in-demand items such as iPhones and AirPods, at the expense of less profitable and lower-demand items.

CFRA analyst Angelo Zino told Reuters that Cook’s somewhat cryptic statement “largely reflects the timing of new product releases”—specifically, new iPhone releases in September. Counterpoint Research Director Jeff Fieldhack speculates from the flip side of the same coin, saying the company will likely direct supply chain “pain” to its least lucrative products. “Assuming Apple prioritizes the iPhone 12 family, it probably affects iPads, Macs, and older iPhones more,” Fieldhack said.

Processor manufacturer AMD has also been carefully managing its supply chain in response to pandemic-induced shortages. With flagship products that finally outperform rival Intel’s, AMD is focusing on the more profitable high end of the market while leaving the economy segment—until a few years ago, its strongest performer—to Intel. “We’re focusing on the most strategic segments of the PC market,” CEO Lisa Su told investors on a conference call.

Apple and AMD are two of semiconductor foundry TSMC’s largest customers—but the problem isn’t limited to TSMC. Intel, which operates its own foundries, acknowledges supply problems of its own. Intel CEO Pat Gelsinger told the BBC that shortages will get worse in the second half of 2021—and that it will be “a year or two” before supplies return to normal.

Gelsinger played up the importance of building new foundries, as Intel is currently doing in Arizona. But he warns that the foundries will take time to get up to speed and begin alleviating shortages—predicting “a year to two years until we’re back to some reasonable supply-demand balance.” This news arrives on the heels of a delay Intel announced this week for its forthcoming 7 nm process, now not expected until 2022.

In some ways, Intel may actually benefit long-term from the pandemic-related supply chain shortages. Although Intel is falling behind rivals AMD and Apple in both performance and power efficiency, the market can only move so far in the absence of supply.

With all vendors selling essentially every processor they can build, Intel’s long-standing ability to produce 80 percent of the world’s x86 desktop CPUs and 90 percent of x86 data center CPUs cements its place in the market—for now—despite ceding performance crowns to its rivals.

Read original article here

Shoe, backpack shortages could be possible for back-to-school shopping

In a year where there have been shortages on everything from Grape-Nuts cereal to chicken wings, another is looming that could affect students’ return to school.

Experts say it’s possible some school supplies could be harder to find and may sell out. Plus, prices may be on the rise.

Neil Saunders, managing director of consultancy GlobalData Retail, told USA TODAY he expects demand will be high on products like backpacks, sneakers, some gadgets and stationery.

“While we are unlikely to see apocalyptic shortages, the continued pressure on supply chains means that not all retailers will get an optimal amount of supply,” Saunders said. “What this means is consumers will have less choice, and some may not be able to get exactly what they want, especially towards the end of the back-to-school season.”

►Save better, spend better:  Money tips and advice delivered right to your inbox. Sign up here

►Back-to-school season: 15 must-have school supplies your kids need, by grade

Last year as more students started the school year virtually amid the pandemic, parents struggled to find desks and chairs.

According to the National Retail Federation’s annual survey, consumers plan to spend record amounts for both school and college supplies with more students planning to return to in-person classrooms this fall.

Families with children in elementary through high school plan to spend an average of $848.90 on school items, which is $59 more than last year. Total back-to-school spending is expected to reach a record $37.1 billion, up from $33.9 billion last year, the survey of more than 7,700 consumers showed.

USA TODAY found that Target and Walmart stores in Florida and California had well-stocked school supply sections.

Will school supplies cost more?

Keith Jelinek, managing director of the retail practice at Berkeley Research Group, urges consumers to start planning their back-to-school shopping sooner rather than later to avoid shortages and possible price increases.

“We are seeing instances where demand is outpacing supply of goods, especially in apparel,” Jelinek told USA TODAY. “Consumers might see the apparel or sneakers item they want but may not be able to get it in the size or color they need.”

With 6% inflation in apparel, he said consumers should anticipate paying anywhere from 10% to 15% more compared to last year. Also, he expects retailers will reduce discounts.

Nikki Baird, vice president of retail innovation at Aptos, a technology solutions provider that works with brands and retailers including Dick’s Sporting Goods, Tilly’s, Carter’s, Skechers and New Balance, agrees that there may be fewer promotions this year.

Baird said stores have also narrowed their assortments to minimize their risk of products not selling.

Early school shopping

More than half of back-to-school shoppers from the the retail federation’s survey said they already started shopping for the school year as of early July, but 76% were still waiting on school supply lists.

“I think there’s a lot of pressure for consumers to shop sooner than later,” Baird said. “There’s a lot of concern out there about inflation, and whether prices are going to go up, there’s lots of disruption around the supply chain.”

Upcoming sales tax holidays are expected to drive shoppers in some states to get a handle on their shopping. According to the International Council of Shopping Centers survey, 38% plan their back-to-school shopping around specific promotional events and dates such as sales-tax holidays and sales.

Saunders said shortages will be patchy and consumers will need to search more than usual to find what they want.

“Consumers seem to be aware of some of these challenges, which is why more are getting their back-to-school shopping out of the way earlier than usual.”

►Free school supplies: Cashback app Ibotta giving away free school supplies for back to school at Walmart, Target and more

►Carrot recall: Grimmway Farms recalls O Organics, Bunny-Luv carrots for possible salmonella contamination

Follow USA TODAY reporter Kelly Tyko on Twitter: @KellyTyko. For more shopping tips and deals, join us on our Shopping Ninjas Facebook group. 



Read original article here

China manufacturing slows as supply shortages roil Asia industry

Growth in China’s June factory activity dipped to a four-month low on higher raw material costs, a shortage of semiconductors and a COVID-19 outbreak in the major export province of Guangdong, amid wider supply chain disruptions in Asia.

The chip supply crunch has hammered other manufacturing powerhouses in Asia. Industrial output in Japan and South Korea slumped in May from the previous month as auto production declined due to semiconductor shortages, adding to concerns of flagging momentum in their respective economies.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

China’s June official manufacturing Purchasing Manager’s Index (PMI) eased slightly to 50.9 versus 51.0 in May, data from the National Bureau of Statistics showed on Wednesday. It, however, exceeded analysts’ forecast for a slowdown to 50.8.

It remained above the 50-point mark that separates growth from contraction on a monthly basis.

“This was largely a result of COVID, which has affected factory output and also new export orders due to the rising waves of infections and resultant restrictions in some neighboring economies,” said Iris Pang, Great China chief economist at ING.

“Overall, (it’s) not a great month but no really worrying signs…China’s growth rate is still positive, though it would be a lot lower in H2 than H1, mostly because of the change in base effects,” said Pang, referring to year-ago comparisons with 2020’s pandemic disruptions.

CHINA’S DIDI WILL REPORTEDLY PRICE IPO ABOVE EXPECTED RANGE

The sub-index for production eased to 51.9, a four-month low, from 52.7 the previous month. Zhao Qinghe, a senior statistician at the NBS, attributed the slowdown in production to constraining factors such as a shortage of semiconductors, inadequate coal supply, a power crunch and maintenance of equipment.

A shortage of coal supply in China’s southern regions, which started in mid-May, hit factory operations though the government has said the power crunch should ease soon.

New export orders fell for a second consecutive month in June and at a faster pace, likely due to the global resurgence of COVID-19 variants, forcing some countries to reimpose lockdowns.

A sub-index for raw material costs in the official PMI stood at 61.2 in June, compared with May’s 72.8, as the government cracked down on high raw material prices.

Growth in new orders, however, picked up, as domestic demand improved.

The world’s second-largest economy has largely recovered from disruptions caused by the pandemic, but Gross Domestic Product (GDP) growth is set to moderate.

“Much of the recovery has occurred and the momentum is slowing. Combined with a relatively higher base, this means year-on-year GDP growth is expected to slow to 7.2% in Q2 from 18.3% in Q1,” said analysts at HSBC.

However, in two-year average terms, they expect growth to pick up to 5.2% from 5.0%, though this is still below pre-pandemic levels of 6.0% growth.

An outbreak of coronavirus infections in China’s major export province of Guangdong has also disrupted shipments.

The official non-manufacturing Purchasing Managers’ Index (PMI) fell to 53.5 in June from 55.2 in May, a separate survey from the NBS showed, dampened by a sharp pull-back in the recovery of the services sector due to local COVID outbreaks.

CLICK HERE TO READ MORE ON FOX BUSINESS

The construction index held steady at 60.1, although analysts expect the sector to face headwinds amid Beijing’s clampdown on the property market.

 (Additional reporting by Colin Qian; Editing by Jacqueline Wong)

Read original article here

Nvidia Is Bringing Back Older GPUs To Deal With Shortages

As supply of Nvidia’s new 30-series graphics cards still struggles to meet demand, the GPU manufacturer is now looking to release more stock of its older cards into the market. A report by PC World has confirmed that Nvidia will be releasing more stock of the RTX 2060 and GTX 1050 Ti to its board partners to help cover demand.

While the brand-new 30-series GPUs are at the forefront of the graphics card shortages, it’s difficult to buy any graphics card right now, with prices on older boards often inflated well above their launch prices. The RTX 2060, for example, is listed between $750 and $800 on Newegg, well above its original launch price of $350 in January 2019.

The choice in re-released boards is strategic, with the older boards not requiring the parts that are rumored to be causing manufacturing bottlenecks for new-generation cards and consoles. As the PC World report points out, the 2016 GTX 1050 Ti also lacks the required amount of dedicated video memory to mine the popular cryptocurrency Ethereum, meaning the new stock won’t be snapped up by crypto miners before gamers can get to it.

In a statement sent to PC World, Nvidia said: “The [GeForce RTX 2060 and GTX 1050 Ti] were never EOLed [end-of-lifed]. So ‘reviving’ seems like the wrong terminology to use here. More of an ebb and flow really. We’re just meeting market demand which remains extremely high as you noted.”

The cheapest card in Nvidia’s new series, the RTX 3060, is due to release in February for $330, though it will likely be subject to the same price inflation and supply issues as the other cards in the series.

“,”480″:”“}},”siteType”:”responsive web”,”startMuted”:false,”startTime”:0,”title”:”NVIDIA%20RTX%203060%20GPU%20Announcement%20-%20CES%202021″,”tracking”:[{“name”:”SiteCatalyst”,”category”:”qos”,”enabled”:true,”params”:[{“name”:”charSet”,”value”:”UTF-8″},{“name”:”currencyCode”,”value”:”USD”},{“name”:”siteType”,”value”:”responsive web”},{“name”:”trackingServer”,”value”:”saa.gamespot.com”},{“name”:”visitorNamespace”,”value”:”cbsinteractive”},{“name”:”heartbeatTrackingServer”,”value”:”cbsinteractive.hb.omtrdc.net”},{“name”:”heartbeatVisitorMarketingCloudOrgId”,”value”:”10D31225525FF5790A490D4D@AdobeOrg”},{“name”:”partnerID”,”value”:”gamespot”},{“name”:”siteCode”,”value”:”gamespot”},{“name”:”brand”,”value”:”gamespot”},{“name”:”account”,”value”:”cbsigamespotsite”},{“name”:”edition”,”value”:”uk”}]},{“name”:”ComScore_ss”,”category”:”qos”,”enabled”:true,”params”:[{“name”:”c2″,”value”:”31824268″},{“name”:”publishersSecret”,”value”:”2cb08ca4d095dd734a374dff8422c2e5″},{“name”:”c3″,”value”:””},{“name”:”partnerID”,”value”:”gamespot”},{“name”:”c4″,”value”:”gamespot”}]},{“name”:”NielsenTracking”,”category”:”tracking”,”enabled”:true,”params”:[{“name”:”host”,”value”:”https://secure-us.imrworldwide.com/cgi-bin/m?”},{“name”:”scCI”,”value”:”us-200330″},{“name”:”scC6″,”value”:”vc,c01″}]},{“name”:”MuxQOSPluginJS”,”category”:”qos”,”enabled”:true,”params”:[{“name”:”propertyKey”,”value”:”b7d6e48b7461a61cb6e863a62″}]}],”trackingAccount”:”cbsigamespotsite”,”trackingPrimaryId”:”cbsigamespotsite”,”trackingSiteCode”:”gs”,”userId”:0,”uvpHi5Ima”:”https://s0.2mdn.net/instream/html5/ima3.js”,”uvpc”:””,”videoAdMobilePartner”:”mobile_web%2Fgamespot.com_mobile”,”videoAdPartner”:”desktop%2Fgamespot.com”,”videoAssetSource”:”Publisher Asset”,”videoStreams”:{“adaptive_stream”:”https://gamespotvideo.cbsistatic.com/vr/2021/01/12/636789/Breakout_Nvidia_RTX3060_20210112_700,1000,1800,2500,3200,4000,master.m3u8″,”adaptive_dash”:”https://gamespotvideo.cbsistatic.com/vr/2021/01/12/636789/Breakout_Nvidia_RTX3060_20210112_700,1000,1800,2500,3200,4000,master.mpd”,”adaptive_hd”:”https://gamespotvideo.cbsistatic.com/vr/2021/01/12/636789/Breakout_Nvidia_RTX3060_20210112_4000,master.m3u8″,”adaptive_high”:”https://gamespotvideo.cbsistatic.com/vr/2021/01/12/636789/Breakout_Nvidia_RTX3060_20210112_2500,master.m3u8″,”adaptive_low”:”https://gamespotvideo.cbsistatic.com/vr/2021/01/12/636789/Breakout_Nvidia_RTX3060_20210112_700,master.m3u8″,”adaptive_restricted”:”https://gamespotvideo.cbsistatic.com/vr/2021/01/12/636789/Breakout_Nvidia_RTX3060_20210112_700,1000,1800,2500,master.m3u8″},”videoType”:”video-on-demand”,”watchedCookieDays”:1,”watchedCookieName”:”watchedVideoIds”}” data-non-iframe-embed=”1″>

You need a javascript enabled browser to watch videos.

Want us to remember this setting for all your devices?

Sign up or Sign in now!

Please use a html5 video capable browser to watch videos.

This video has an invalid file format.

Sorry, but you can’t access this content!

Please enter your date of birth to view this video

By clicking ‘enter’, you agree to GameSpot’s

Terms of Use and
Privacy Policy

Now Playing: NVIDIA RTX 3060 GPU Announcement – CES 2021



Read original article here

Vaccine Shortages Hit E.U. in a Setback for Its Immunization Race

BRUSSELS — Europe’s coronavirus vaccination woes snowballed into a full-blown crisis Wednesday, as Spain became the first country to partly suspend immunizations for lack of doses, and a dispute escalated with AstraZeneca over the drugmaker’s announcement that it would slash deliveries of its vaccine by 60 percent because of production shortfalls.

The European Union has been beset by a litany of problems since it approved its first coronavirus vaccine, made by Pfizer and BioNTech, in December and rushed to begin a vast immunization campaign weeks behind rich nations like the United States and Britain.

While it is flush with cash, influence and negotiating heft, the bloc of 27 nations has found itself behind those countries, as well as others like Israel, Canada, and the United Arab Emirates, mounting similar efforts to get enough doses for their citizens, even as many countries across the world, particularly poorer ones, struggle to secure any at all.

The European Commission, the bloc’s executive branch, last week set a goal to have 70 percent of its population inoculated by this summer, a goal that was dismissed four days later by the president of the European Council, Charles Michel, as “difficult.”

By this week, a mere 2 percent of E.U. citizens had received at least one dose of a coronavirus vaccine, according to numbers collected by Our World in Data, compared with some 40 percent of Israelis. The figure in Britain was 11 percent, and just over 6 percent in the United States.

In a rare bit of good news, the French drugmaker Sanofi said Wednesday that it would help produce more than 100 million doses of the Pfizer-BioNTech vaccine, starting this summer, but those doses would likely come too late to salvage vaccination plans for the first half of 2021.

Pfizer informed the European Union and other countries outside the United States this month that it had to drastically cut its vaccine deliveries until mid-February to upgrade its plants in order to ramp up output, adding to the severe supply problems facing the region.

But it was AstraZeneca’s sudden announcement last week that it would cut deliveries in February and March by 60 percent, that really upended European Union vaccination plans. Many countries had built their strategies around expectations of millions of those doses of that vaccine, which is cheaper and easier to store than others, in the first quarter of the year. AstraZeneca said it was having production troubles at one of its factories, but did not specify what those were or offer details on how it was addressing them and when.

The AstraZeneca vaccine is expected to gain approval for use in the European Union on Friday, and the bloc had been expecting some 80 million doses to be delivered in the course of the next two months.

With the company now saying it can’t make good on its promise to deliver, it is unclear when the bloc’s target might be reached.

Some critics have blamed the European Commission for the mess. The commission struck deals on behalf of its 27 member states to secure a total of 2.3 billion vaccine doses from several companies. But some of its agreements lagged behind those struck by the United States and Britain by weeks. AstraZeneca and some European opposition politicians say the delay put the bloc at the back of the line for deliveries.

But the commission has hit back against the criticism.

“We reject the logic of first-come first-served,” the bloc’s heath commissioner, Stella Kyriakides said at a news conference Wednesday. “That may work at the neighborhood butcher, but not in contracts and not in our advanced purchase agreements. There’s no priority clause in the advanced purchase agreement,” she said.

AstraZeneca needed “to live up to its contractual, societal and moral obligations,” she said.

The bloc’s drug regulator, the European Medicines Agency, has also been accused of being too bureaucratic and taking too long to grant authorization to vaccines. The agency has rejected that criticism, defending its processes as being more thorough, by spending more time with data from clinical trials and going back repeatedly to pharmaceutical companies for additional details.

The vaccine crisis in the European Union is set against a still-raging second wave of the coronavirus, prolonged lockdowns in most member countries, and widespread panic over the spread of at least two highly infectious variants of the virus that are bringing national health systems to their knees yet again. France, which has imposed restrictions on social and economic life since a second wave of the coronavirus began to overwhelm it in late October, is now considering moving into an even stricter lockdown like the one it had imposed in the springtime.

The pain of supply shortages is being felt across Europe, with Spain announcing Wednesday that it would suspend the vaccination program in Madrid for two weeks, and warning that Catalonia, in the northeast of the country, may follow suit.

“Tomorrow our fridges will be empty,” Josep Maria Argimon, a regional health official in Catalonia, said, referring to the dwindling supplies of the vaccine.

The deputy head of Madrid’s regional government, Ignacio Aguado, told a news conference that priority needed to be given to administering the second dose of the vaccine and that Madrid did not have enough supplies to continue with the first round of vaccinations.

Mr. Aguado called on the central government to urgently demand extra supplies from the European Union, saying that it needed to “go to Brussels and get more doses” for Spain.

The sentiment was also expressed by local-government leaders in other E.U. countries.

“My conviction is that there is a real shortage of vaccines,” Martine Aubry, the mayor of the northern French city of Lille said this month, as she urged the French government to “tell the truth.” François Rebsamen, the mayor of Dijon, in northeastern France, decried “the central government’s failure to deliver vaccines.”

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.

Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.

Yes, but not forever. The two vaccines that will potentially get authorized this month clearly protect people from getting sick with Covid-19. But the clinical trials that delivered these results were not designed to determine whether vaccinated people could still spread the coronavirus without developing symptoms. That remains a possibility. We know that people who are naturally infected by the coronavirus can spread it while they’re not experiencing any cough or other symptoms. Researchers will be intensely studying this question as the vaccines roll out. In the meantime, even vaccinated people will need to think of themselves as possible spreaders.

The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection won’t be any different from ones you’ve gotten before. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. But some of them have felt short-lived discomfort, including aches and flu-like symptoms that typically last a day. It’s possible that people may need to plan to take a day off work or school after the second shot. While these experiences aren’t pleasant, they are a good sign: they are the result of your own immune system encountering the vaccine and mounting a potent response that will provide long-lasting immunity.

No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

And in Germany, the bloc’s richest and largest country, regional leaders were livid about the shortages, for which they blamed their own government and the European Union.

“I have to say that I am totally disappointed with how this has played out,” Manuela Schwesig, governor of the northeastern state of Mecklenburg-Western Pomerania said last week.

“We had a very clear agreement — we in the states prepare the immunization centers and set everything up. We have done that. The logistics are there and we could offer an inoculation to all of our citizens,” Ms. Schwesig said on the ZDF public television network. “But we can’t use it because we don’t have enough vaccines.”

Delays in ordering and approving vaccines, and the current shortages, have not been the only problems, experts said.

“Some countries have planned the entire process well in advance and have done their job in an efficient and effective way,” said Rosanna Tarricone of Bocconi University in Milan. But while the E.U. countries “have announced their plans, they haven’t actually planned anything appropriately.”

In parts of the European Union, especially in its poorer eastern flank, people have been struggling to access vaccines because of a lack of trained nurses, needles and syringes, or poor administration and communication with citizens.

Still, despite the growing concerns and political fallout, experts warned against adopting the British policy of allowing up to 12 weeks to pass between the first and second doses of two-dose vaccines such as the Pfizer and Moderna ones.

In the European Union, regulators have recommended allowing a maximum of three weeks between the two Pfizer doses, or four weeks in the case of the Moderna vaccine.

“In the E.U., at the national level everybody tries to go as fast as possible, because this is what we need to do,” said Jean-Michel Dogné, a professor at the University of Namur in Belgium and adviser to the European Medicines Agency and the World Health Organization. “But we need to be careful to be able to give the second dose, and to anticipate new vaccines that may come.”

Raphael Minder contributed reporting from Madrid, Melissa Eddy from Berlin, and Constant Meheut and Aurelien Breeden from Paris.

Read original article here

Global COVID-19 cases surpass 100 million as nations tackle vaccine shortages

(Reuters) – Global coronavirus cases surpassed 100 million on Wednesday, according to a Reuters tally, as countries around the world struggle with new virus variants and vaccine shortfalls.

A health worker approaches a motorist at a COVID-19 drive-through testing site of a Dis-Chem pharmacy, amid a nationwide coronavirus disease (COVID-19) lockdown, in Midrand, South Africa, January 18, 2021. REUTERS/Siphiwe Sibeko

Almost 1.3% of the world’s population has now been infected with COVID-19, the disease caused by the novel coronavirus, and more than 2.1 million people have died.

One person has been infected every 7.7 seconds, on average, since the start of the year. Around 668,250 cases have been reported each day over the same period, and the global fatality rate stands at 2.15%.

The worst-affected countries – the United States, India, Brazil, Russia and the United Kingdom – make up more than half all reported COVID-19 cases but represent 28% of the global population, according to a Reuters analysis.

It took the world 11 months to record the first 50 million cases of the pandemic, compared to just three months for cases to double to 100 million. (Graphic: tmsnrt.rs/34pvUyi)

Around 56 countries have begun vaccinating people for the coronavirus, administering at least 64 million doses. Israel leads the world on per capita vaccinations, inoculating 29% of its population with at least one dose.

UNITED STATES

With over 25 million cases, the United States has 25% of all reported COVID cases although it accounts for just 4% of the world’s population. The United States leads the world in the daily average number of new deaths reported, accounting for one in every five deaths reported worldwide each day. With just under 425,00 fatalities, the United States has reported almost twice as many deaths as Brazil, which has the second-highest death toll in the world.

As the worst-affected region in the world, Europe is currently reporting a million new infections about every four days and has reported nearly 30 million since the pandemic began. Britain on Tuesday reached 100,000 deaths.

The Eastern European region, including countries like Russia, Poland and Ukraine, contribute to nearly 10% of all global COVID-19 cases.

Despite securing deals for vaccine supplies early on, many European countries are facing delays in shipments from both Pfizer Inc and AstraZeneca Plc

ASIA AND AFRICA

In India, the nation with the second-highest number of cases, infections are decreasing, with almost 13,700 new infections reported on average each day – around 15% of its peak. Prime Minister Narendra Modi said on Friday India was completely self-reliant on coronavirus vaccine supplies as the world’s second-most populous country inoculated more than 1 million people within a week of starting its campaign.

China, which recently marked the first anniversary of the world’s first coronavirus lockdown in the central city of Wuhan, is facing its worst wave of local cases since March last year.

As richer nations race ahead with mass vaccination campaigns, Africa is still scrambling to secure supplies as it grapples with concerns about more-infectious variants of the virus first identified in South Africa and Britain.

According to the Reuters tally, African countries have nearly 3.5 million cases and over 85,000 deaths.

The South African variant, also known as 501Y.V2, is 50% more infectious and has been detected in at least 20 countries.

U.S. President Joe Biden will impose a ban on most non-U.S. citizens entering the country who have recently been in South Africa starting Saturday in a bid to contain the spread of a new variant of COVID-19.

Australia and New Zealand have fared better than most other developed economies during the pandemic through swift border closures, lockdowns, strict hotel quarantine for travellers and widespread testing and social distancing.

“We have the virus under control here in Australia, but we want to roll out the vaccine,” Australian Treasurer Josh Frydenberg told a news conference on Sunday.

Reporting by Shaina Ahluwalia and Roshan Abraham in Bengaluru; Editing by Lisa Shumaker and Jane Wardell

Read original article here

Health experts blame rapid expansion for vaccine shortages

Public health experts Thursday blamed COVID-19 vaccine shortages around the U.S. in part on the Trump administration’s push to get states to vastly expand their vaccination drives to reach the nation’s estimated 54 million people age 65 and over.

The push that began over a week ago has not been accompanied by enough doses to meet demand, according to state and local officials, leading to frustration and confusion and limiting states’ ability to attack the outbreak that has killed over 400,000 Americans.

Over the past few days, authorities in California, Ohio, West Virginia, Florida and Hawaii warned that their supplies were running out. New York City began canceling or postponing shots or stopped making new appointments because of the shortages, which President Joe Biden has vowed to turn around. Florida’s top health official said the state would deal with the scarcity by restricting vaccines to state residents.

The vaccine rollout so far has been “a major disappointment,” said Dr. Eric Topol, head of the Scripps Research Translational Institute.

Problems started with the Trump administration’s “fatal mistake” of not ordering enough vaccine, which was then snapped up by other countries, Topol said. Then, opening the line to senior citizens set people up for disappointment because there wasn’t enough vaccine, he said. The Trump administration also left crucial planning to the states and didn’t provide the necessary funding.

“It doesn’t happen by fairy dust,” Topol said. “You need to put funds into that.”

Last week, before Biden took over as president, the U.S. Health and Human Services Department suggested that the frustration was the result of unrealistic expectations among the states as to how much vaccine was on the way.

But some public health experts said that the states have not been getting reliable information on vaccine deliveries and that the amounts they have been sent have been unpredictable. That, in turn, has made it difficult for them to plan how to inoculate people.

“It’s a bit of having to build it as we go,” said Dr. George Rutherford, an epidemiologist at the University of California, San Francisco. “It’s a front-end supply issue, and unless we know how much vaccine is flowing down the pipe, it’s hard to get these things sized right, staffed, get people there, get them vaccinated and get them gone.”

State health secretaries have asked the Biden administration for earlier and more reliable predictions on vaccine deliveries, said Washington state Health Secretary Dr. Umair Shah.

Dr. Marcus Plescia of the Association of State and Territorial Health Officials was also among those who said opening vaccinations to senior citizens was done too soon, before supply could catch up.

“We needed steady federal leadership on this early in the launch,” Plescia said. “That did not happen, and now that we are not prioritizing groups, there is going to be some lag for supply to catch up with demand.”

Supply will pick up over the next few weeks, he said. Deliveries go out to the states every week, and the government and drugmakers have given assurances large quantities are in the pipeline.

The rollout has proceeded at a disappointing pace. The U.S. government has delivered nearly 38 million doses of vaccine to the states, and about 17.5 million of those have been administered, according to the Centers for Disease Control and Prevention.

About 2.4 million people have received the necessary two doses, by the CDC’s count — well short of the hundreds of millions who will have to be inoculated to vanquish the outbreak.

Biden, in one of his first orders of business, signed 10 executive orders to combat the coronavirus pandemic on Thursday, including one broadening the use of the Defense Production Act to expand vaccine production. The 1950 Korean War-era law enables the government to direct the manufacture of critical goods.

He also mandated masks for travel, including in airports and on planes, ships, trains, buses and public transportation, and ordered the Federal Emergency Management Agency to set up vaccination centers and the CDC to make vaccines available through pharmacies starting next month.

Biden has vowed to dispense 100 million shots in his first 100 days.

“We’ll move heaven and earth to get more people vaccinated for free,” he said.

Florida was one of the first states to open vaccine eligibility to members of the general public over 65. Now uncertainty over the vaccine supply has prompted the state surgeon general, Scott Rivkees, to advise counties to prioritize available doses for state residents, including so-called snowbirds who live there part-time. People seeking vaccination will have to provide a driver’s license or other document, such as rental leases and utility bills.

In New York, Mayor Bill de Blasio and Gov. Andrew Cuomo have been pleading for more doses. Appointments through Sunday for the first dose of the vaccine at 15 community vaccination hubs set up by the city health department were postponed to next week.

Vaccinations in New York haven’t stopped, but demand for the shots now far exceeds the number of doses available, the mayor said.

“It’s just tremendously sad that we have so many people who want the vaccine and so much ability to give the vaccine, what’s happening?” de Blasio said. “For lack of supply, we’re actually having to cancel appointments.”

Rosa Schneider had jumped at the chance to make a vaccination appointment once she heard that educators like her were eligible in New York. A high school English teacher who lives in New York City but works in New Jersey, she said that a day before she was to be vaccinated on Wednesday at a city-run hospital, she got a call saying the supply had run out and the appointment was canceled.

“I was concerned, and I was upset,” said Schneider, 32, but she is trying daily to book another appointment. She is hopeful availability will improve in the coming weeks.

___

Associated Press writer Jennifer Peltz contributed to this report from New York.

Read original article here